Prime Medicine Inc
NASDAQ:PRME
ROE
Return on Equity
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
ROE Across Competitors
| Country | Company | Market Cap | ROE | ||
|---|---|---|---|---|---|
| US |
P
|
Prime Medicine Inc
NASDAQ:PRME
|
407.9m USD |
-115%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
115%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
334.3B USD |
88%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
160.4B USD |
106%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
139.1B USD |
33%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
118.1B USD |
-6%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-877%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
116.7B AUD |
15%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
59.2B USD |
16%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
-28%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
43B USD |
519%
|
Prime Medicine Inc
Glance View
Prime Medicine Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Cambridge, Massachusetts. The company went IPO on 2022-10-20. Prime Medicine, Inc. is a United States-based biotechnology company. The firm is engaged in multiple drug discovery programs that target liver, eye, ex-vivo hematopoietic stem cell and neuro-muscular indications. The firm's Prime Editing, a transformative technology that addressed the cause of genetic disease. The firm's collaborative approach help fight disease and accelerating the development of Prime Editing to deliver therapies for patients. Its Prime Editing is used to modify gene-regulatory sequences. These edits can be made in therapeutically relevant cells and organs, including specialized terminally differentiated cells. Its Prime Editing acts as a Deoxyribonucleic acid (DNA) word processor, with the power to search and replace genetic sequences at their exact location in the genome, all without making double-strand breaks in DNA.
See Also
ROE, or Return on Equity, is a key financial ratio that measures a company's profitability. Specifically, it measures how many dollars of profit are generated for each dollar of shareholder's equity. A higher ROE indicates better financial performance and effective use of capital, making it a valuable metric for investors assessing a company's earning potential.
Based on Prime Medicine Inc's most recent financial statements, the company has ROE of -115.2%.
You don't have any saved screeners yet